FOLD
Featured PickAmicus Therapeutics, Inc.
Real picks. Real tracking. We bet on one stock daily and show you exactly how it plays out.
AI Confidence Score
82
Entry Price
$14.34
Current Price
$41.66
Total Return
+0.00%
vs SPY
+0.00%
As of Close 2026-02-18
Executive Summary
Amicus Therapeutics (FOLD) enters today's Q4 earnings print as a coiled spring, with the potential to shatter the $14.50 merger-arb peg established by the BioMarin acquisition offer. While the market has priced in a quiet march to the deal close, a beat on Galafold revenue would expose the $14.50 bid as undervalued, triggering a 'repricing squeeze' that forces arbitrage shorts to cover. This setup perfectly aligns with the current 'Flight to Quality' regime, where profitable, defensive biotechs are attracting capital away from speculative weakness.
Technical Context
Setup
The stock is compressing just 0.3% below its 52-week high with volume at only 0.3x the 20-day average, creating a textbook volatility squeeze setup backed by a top-tier Cohort Score of 16.0.
Invalidation (Stop)
Thesis is invalidated if price breaks support at $14.27, which would signal deal risk or regulatory hurdles rather than a valuation squeeze.
Runner-ups
Recent Performance History
17 Total Picks • 62% Win Rate (7d)
| Date | Ticker | Entry | Last | Gain/Loss | 7d | 30d | 60d |
|---|---|---|---|---|---|---|---|
| 2026-02-17 | ROL | $60.08 | $60.25 | +0.28% | N/A | N/A | N/A |
| 2026-02-13 | AES | $16.28 | $16.29 | +0.06% | N/A | N/A | N/A |
| 2026-02-12 | PRA | $24.53 | $24.37 | -0.65% | N/A | N/A | N/A |
| 2026-02-11 | AES | $16.44 | $16.29 | -0.91% | -0.91% | N/A | N/A |
| 2026-02-10 | RRX | $222.74 | $218.46 | -1.92% | -1.66% | N/A | N/A |
| 2026-02-09 | AES | $16.06 | $16.29 | +1.43% | +2.05% | N/A | N/A |
| 2026-02-06 | ZWS | $52.78 | $51.21 | -2.97% | -2.80% | N/A | N/A |
| 2026-02-05 | AVY | $192.88 | $195.41 | +1.31% | +1.38% | N/A | N/A |
| 2026-02-04 | RRX | $178.30 | $218.46 | +22.52% | +25.68% | N/A | N/A |
| 2026-02-03 | EPD | $34.63 | $36.11 | +4.27% | +1.62% | N/A | N/A |
Schema v1.0 | Pipeline v1.2.0